Curr Opin Cardiol 2021 Apr 28. Epub 2021 Apr 28.
LMC Diabetes & Endocrinology, Concord, Ontario Division of Endocrinology and Metabolism, St Michael's Hospital of Unity Health Toronto, Toronto, Ontario Division of Endocrinology, Trillium Health Partners, Mississauga, Ontario Department of Medicine, University of Toronto, Toronto, Ontario Division of Endocrinology and Metabolism, Sunnybrook Health Sciences Centre, Toronto, Ontario Division of Cardiology, Hamilton Health Sciences, Hamilton, Ontario Department of Medicine and The Population Health Research Institute, McMaster University, Hamilton, Ontario C-endo Diabetes and Endocrinology Clinic, Calgary, Alberta Division of Cardiac Surgery, St Michael's Hospital of Unity Health Toronto, Ontario Departments of Surgery, and Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada.
Purpose Of Review: Elevated levels of triglycerides, independent of low-density lipoprotein cholesterol (LDL-C) levels and statin therapy, are associated with heightened cardiovascular risk.
Recent Findings: Mixed omega-3 fatty acid formulations, which contain varying amounts of docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), lower triglycerides levels but trial results with omega-3 fatty acids combinations have generally been neutral for cardiovascular outcomes. In contrast, the REDUCE-IT trial with icosapent ethyl (IPE), a highly purified ethyl ester of EPA, demonstrated reduced cardiovascular risk in individuals with established atherosclerotic cardiovascular disease or diabetes with at least one additional risk factor, despite having relatively well controlled LDL-C levels but triglycerides at least 135 mg/dl while on statin therapy. Read More